Pfizer vaccine protects from first dose, says FDA – news

Safety data from the 38,000-participant clinical trial of the vaccine “suggests a favorable safety profile, without identifying specific safety concerns that prevent” authorization, FDA experts wrote.

The Pfizer vaccine began being applied in the UK on Tuesday, less than a week after its emergency use was approved by that country’s regulatory body.

/ Embedded code reception /

/ End of embed code /

They also submitted an application for authorization for its use in Argentina a week ago to the National Administration of Drugs, Food and Medical Technology (Anmat).

Results from phase 3 clinical trials of this vaccine showed an efficacy rate of 95% in participants without prior SARS-CoV-2 infection and in participants with and without prior SARS-CoV-2 infection. measured from 7 days after the second dose.

The Pfizer and BioNTech vaccine uses an innovative technology called messenger RNA.

These types of vaccines directly use the genetic code of a viral protein (in this case the spike protein is used). Upon entering the body, cells “produce” this protein and, recognizing it, activates the immune system.